Intraperitoneal chemotherapy for ovarian cancer: challenges and future directions
Alexandra King
This article has no abstract so we have provided the first paragraph of the full text.
The high incidence of complications and toxicities associated with intraperitoneal chemotherapy (IPC) in women with ovarian cancer has previously been noted. Despite reports that IPC significantly improves progression-free and overall survival when compared with systemic chemotherapy, many patients undergoing IPC do not complete therapy. In a recent Gynecologic Oncology paper, Walker et al. discuss patient characteristics and complications associated with the 205 women enrolled in the IPC arm of the phase III Gynecologic Oncology Group trial 172.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Mal-function of TLRs by SOCSNature Immunology News and Views (01 Feb 2006)
Solar size variationNature News and Views (31 Jul 1980)